Citius Pharmaceuticals Executes Definitive Agreement To Merge Wholly Owned Subsidiary With TenX Keane Acquisition To Form Publicly Listed Citius Oncology, Inc.
Citius Pharmaceuticals Executes Definitive Agreement To Merge Wholly Owned Subsidiary With TenX Keane Acquisition To Form Publicly Listed Citius Oncology, Inc.
Citius Pharmicals簽署最終協議，將全資子公司與收購TenX Keane合併，組建上市的Citius Oncology, Inc.
Upon closing, pursuant to the terms of the merger agreement, Citius Pharma would receive 67.5 million shares in Citius Oncology at $10 per share and retain majority ownership of approximately 90%. The transaction has been approved by the Board of Directors of both companies and is expected to close in the first half of 2024.
根據合併協定的條款，完成交易後，Citius Pharma將以每股10美元的價格獲得6,750萬股Citius Oncology的股份，並保留大約90%的多數股權。這筆交易已經得到兩家公司董事會的批准，預計將於2024年上半年完成。